ACADIA Pharmaceuticals (ACAD) Competitors

Dr. Reddy's Laboratories (NYSE:RDY) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Do analysts recommend RDY or ACAD?

Dr. Reddy's Laboratories presently has a consensus price target of $17.00, suggesting a potential upside of 17.40%. ACADIA Pharmaceuticals has a consensus price target of $25.75, suggesting a potential upside of 18.72%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
ACADIA Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.57

Does the media prefer RDY or ACAD?

In the previous week, ACADIA Pharmaceuticals had 36 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 47 mentions for ACADIA Pharmaceuticals and 11 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.61 beat ACADIA Pharmaceuticals' score of 0.82 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ACADIA Pharmaceuticals	24 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RDY or ACAD more profitable?

Dr. Reddy's Laboratories has a net margin of 17.25% compared to ACADIA Pharmaceuticals' net margin of 13.83%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	17.25%	17.87%	12.32%
ACADIA Pharmaceuticals	13.83%	25.83%	14.71%

Do institutionals & insiders have more ownership in RDY or ACAD?

3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has preferable earnings and valuation, RDY or ACAD?

Dr. Reddy's Laboratories has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$325.54B	0.04	$668M	$0.66	21.94
ACADIA Pharmaceuticals	$996.28M	3.64	-$61.29M	$1.37	15.83

Does the MarketBeat Community favor RDY or ACAD?

ACADIA Pharmaceuticals received 582 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 72.96% of users gave ACADIA Pharmaceuticals an outperform vote while only 59.41% of users gave Dr. Reddy's Laboratories an outperform vote.

Company	Underperform	Outperform
Dr. Reddy's Laboratories	Outperform Votes 322 59.41%	Underperform Votes 220 40.59%
ACADIA Pharmaceuticals	Outperform Votes 904 72.96%	Underperform Votes 335 27.04%

Which has more risk and volatility, RDY or ACAD?

Dr. Reddy's Laboratories has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Summary

ACADIA Pharmaceuticals beats Dr. Reddy's Laboratories on 14 of the 18 factors compared between the two stocks.